Alnylam Pharmaceuticals, Inc.
Market cap $36.3B
$271.77
ALNY
$271.77
+1.13% today
Buy with €1M virtual cash · No real money
Alnylam Pharmaceuticals, Inc. (ALNY) is a publicly traded company listed on the XNAS. As of July 27, 2026, Invest's signal rates ALNY a Sell, with the stock down 17% over the past year. You can practice trading ALNY risk-free with €1,000,000 in virtual cash.
Key stats
As of July 27, 2026
Market Cap
$36.3B
Volume
1.2M
52-wk High
$495.55
52-wk Low
$262.21
Day High
$275.58
Day Low
$265.64
P/E (TTM)
135.21
Revenue (TTM)
$3.7B
EPS (TTM)
$2.01
Performance
1M
-7.6%
6M
-26.5%
1Y
-16.5%
Invest signal · ALNY
SellAlgorithmic signal from price trend, valuation, and fundamentals — educational only, not financial advice.
ALNY overview
AI overviewRevenue & EPS — last 8 quarters
QoQ rev -12.2%Revenue
$1BEPS (diluted)
$0.82 per shareLatest ALNY news
Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200
GlobeNewswire Inc. · Jul 17
Oligonucleotide CDMO Market to Reach USD 9.87 Billion by 2031 as RNA-Targeted Drug Pipelines Expand
GlobeNewswire Inc. · Jul 15
Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider
GlobeNewswire Inc. · Jul 7
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.
The Motley Fool · Jul 2
Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
GlobeNewswire Inc. · May 18
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam.
Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Employees
2,500
30-Day Win Rate · ALNY
13 days
10 days
Last 23 sessions
How to practice trading ALNY
- 1
Use the ALNY buy panel above
Set a quantity and hit Buy at the real market price — right here, nothing to download.
- 2
Trade with €1,000,000 virtual cash
You get a million in virtual money instantly to invest, risk-free.
- 3
Create a free account to save it
Sign up in seconds to keep your portfolio and track its performance.
- 4
Track and compete
Watch your portfolio grow and climb the global leaderboard — or start a private league.
- 5
Prefer mobile? Get the iOS app
Invest is also free on the App Store, synced with your web account.
Top ALNY traders on Invest
Full leaderboardFrequently asked questions
Is ALNY a good stock to buy right now?
As of July 27, 2026, Invest's signal rates ALNY a Sell, based on its price trend, valuation, and fundamentals (P/E around 135.2), with the stock down 17% over the past year. This is an educational signal, not financial advice — the best way to test the thesis is to practice trading ALNY risk-free first.
What is Alnylam Pharmaceuticals, Inc.'s (ALNY) market cap?
Alnylam Pharmaceuticals, Inc. has a market capitalization of approximately $36.3B, on trailing-twelve-month revenue of about $3.7B.
How has ALNY stock performed?
ALNY is down 17% over the past year and down 27% over six months. Its 52-week range runs roughly from $262.21 to $495.55. Past performance doesn't predict future results.
How can I practice trading ALNY for free?
On Invest you get €1,000,000 in virtual cash and can buy ALNY at real market prices right in your browser — no download and no real money at risk. Create a free account to save your portfolio and track its performance over time.
More stocks to practice
Designs the iPhone, Mac, and a huge services ecosystem.
Windows, Office, Azure cloud, and enterprise software.
The leading designer of AI and gaming GPUs.
E-commerce giant and the largest cloud provider (AWS).
Google Search, YouTube, Android, and cloud.
Facebook, Instagram, WhatsApp, and the metaverse.
Compare ALNY with peers